News & Events zu Nexalin Technology Inc (NXL)NXLNexalin Technology Inc

Nexalin Publishes Clinical Research Results on Alzheimer's Disease

Nexalin Technology announced the publication of a fourth peer-reviewed article reporting results from clinical research on its 15 mA DIFS technology in Alzheimer's disease. The new analysis, published in the Journal of Alzheimer's Disease, found that 15 mA, 40 Hz stimulation delivered with Nexalin's device significantly improved sleep quality in patients with mild Alzheimer's disease compared with sham treatment, with no serious adverse events. It reports a secondary analysis of the TRANSFORM-AD study, a randomized, double-blind, sham-controlled trial whose earlier results, including improvements in cognitive function and hippocampal theta-gamma coupling, were previously published in Alzheimer's Research & Therapy. The study was funded by the National Key R&D Program of China, and the authors declared no conflicts of interest. Patients with mild Alzheimer's disease were randomized 1:1 to active stimulation or sham, delivered with Nexalin's Gen-2 SYNC 15 mA device. The active group received 30 one-hour sessions of 40 Hz stimulation at a peak-to-peak amplitude of 15 mA, administered twice daily over 15 consecutive days with electrodes placed on the forehead and bilateral mastoids. The sham group followed an identical protocol with zero current output; active and sham devices were indistinguishable in appearance and sensation, and participants, caregivers, outcome assessors and research nurses remained blinded throughout. Sleep quality, measured by the Pittsburgh Sleep Quality Index, was the pre-specified primary outcome of the analysis, with anxiety, depression and quality of life evaluated as exploratory outcomes. Of the 46 randomized participants, 43 completed baseline and post-treatment assessments. After adjustment for baseline scores, patients receiving 15 mA stimulation had PSQI scores 2.34 points lower than the sham group at the end of treatment, where lower scores indicate better sleep. Within-group change. Mean PSQI in the active group fell from 9.65 to 6.35, a reduction of 3.30 points, or approximately 34%, compared with a reduction of 0.52 points in the sham group. The treatment effect remained significant after additional adjustment for age, sex, education and baseline cognitive scores and in a mixed-model repeated-measures analysis. No serious adverse events were observed in either group. One patient in the active group reported a transient tingling sensation during the first two sessions, and one patient in the sham group reported transient itching at the first session. The analysis did not provide conclusive evidence of effects on anxiety, depression or quality of life, which were evaluated as exploratory outcomes. The authors note that participants' low baseline anxiety and depression scores may account for these findings and call for larger, adequately powered trials. They also note that sleep quality was measured with a self-reported questionnaire, that the duration of the effect after treatment is not yet known, and that blinding integrity was not formally assessed.

Nexalin Technology Inc Trading Halted Due to Volatility

Nexalin Technology Inc trading halted, volatility trading pause

Onsemi Adjusts Synaptics Acquisition Plans, Stock Up 8%

Stock futures edged higher ahead of September's jobs report and have added to gains after the weaker-than-expected payrolls data. Also helping stocks are oil prices falling sharply from recent highs as European countries are said to consider releasing strategic fuel reserves following pressure from the Trump administration to boost supplies.In pre-market trading, S&P 500 futures rose 0.87%, Nasdaq futures were up 1.17%, and Dow futures added 0.93%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Onsemiup 8% after announcing revised plans to acquire Synapticsfor $123 per share in cash, with Synaptics up 14%Vylorup 4% after coverage was initiated with bullish ratings at RBC Capital, BMO and Morgan StanleyNvidiaup 2% after being reinstated as Morgan Stanley's Top Pick in semisModernaup 1% after being named to replace Warner Bros. Discoveryin the Nasdaq-100 IndexDOWN AFTER EARNINGS -Nikedown 8%LOWER -Western Digitaldown 7% and Seagate Technologydown 10% following a report that said Toshibaplans to double production capacity for hard disk drives used in AI data centersFICOdown 7%, TransUniondown 2%, and Equifaxdown 4% as the FHFA plans to direct Fannie Maeand Freddie Macto require lenders to pull credit data from two major credit reporting bureaus instead of threeNexalindown 20% after announcing a distribution and manufacturing agreement for Brazil